Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 4 3Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 9INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Barrett Esophagus 3

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Esomeprazole × Clear all
NCT00637559 2011-01-25

Barrett's Esophagus - 315 - 3 Way Cross-Over

AstraZeneca

Phase 4 Completed
50 enrolled
Gastrointestinal

Barrett Esophagus

NCT00637988 2011-01-21

Barrett's Esophagus - 315 - 3 Way Cross Over

AstraZeneca

Phase 4 Completed
32 enrolled
Gastrointestinal

Barrett Esophagus

NCT00352261 2009-03-26

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

AstraZeneca

Phase 4 Completed
80 enrolled
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡